“Yes, doctor. My dad’s first fall was on his 65th birthday. He stood in the driveway and suddenly dropped backwards on his back. After he fell two more times, we came to the clinic.” The symptoms the ...

Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE ...

Scientists and clinicians have been aware of Alzheimer's disease, the most common cause of dementia, for decades, but there ...

The Lagos Waste Management Authority (LAWMA), in collaboration with Private Sector Partnership (PSP), has the primary ...

Arvinas (NASDAQ:ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical ...

GemVax & KAEL (hereinafter referred to as GemVax) announced on the 13th that it achieved a consolidated sales revenue of 81.5 billion won last year, ...

The JAMP Pharma Group, a leader in the Canadian pharmaceutical industry, announces the launch of PrJAMP Enzalutamide (Enzalutamide oral capsules) in Canada, strengthening its commitment to improving ...

Newsom trades jabs with Donald Trump after the president sought to revisit a short-lived controversy for the California governor. Gavin ...

Rising diagnoses of young onset dementia highlight the need for early recognition and timely evaluation of a condition that disrupts patients’ careers, families, and financial stability.

Learn about gene expression studies in progressive supranuclear palsy in Mayo Clinic's Precision Medicine in Neurodegeneration Lab led by Nilufer Ertekin-Taner, M.D., Ph.D.